CA2574002A1 - Procede d'inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci - Google Patents

Procede d'inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci Download PDF

Info

Publication number
CA2574002A1
CA2574002A1 CA002574002A CA2574002A CA2574002A1 CA 2574002 A1 CA2574002 A1 CA 2574002A1 CA 002574002 A CA002574002 A CA 002574002A CA 2574002 A CA2574002 A CA 2574002A CA 2574002 A1 CA2574002 A1 CA 2574002A1
Authority
CA
Canada
Prior art keywords
carboxamide
dihydro
azepine
dibenz
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002574002A
Other languages
English (en)
Other versions
CA2574002C (fr
Inventor
David Alexander Learmonth
Guenter Weingaertner
Matthias Kraemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Portela & C.A., S.A.
David Alexander Learmonth
Guenter Weingaertner
Matthias Kraemer
Bial-Portela & Ca, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & C.A., S.A., David Alexander Learmonth, Guenter Weingaertner, Matthias Kraemer, Bial-Portela & Ca, S.A. filed Critical Portela & C.A., S.A.
Publication of CA2574002A1 publication Critical patent/CA2574002A1/fr
Application granted granted Critical
Publication of CA2574002C publication Critical patent/CA2574002C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2574002A 2004-07-13 2005-07-13 Procede d'inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci Active CA2574002C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0415664A GB2416167A (en) 2004-07-13 2004-07-13 Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
GB0415664.2 2004-07-13
PCT/GB2005/002744 WO2006005951A1 (fr) 2004-07-13 2005-07-13 Procede d'inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci

Publications (2)

Publication Number Publication Date
CA2574002A1 true CA2574002A1 (fr) 2006-01-19
CA2574002C CA2574002C (fr) 2014-02-04

Family

ID=32893499

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2574002A Active CA2574002C (fr) 2004-07-13 2005-07-13 Procede d'inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci

Country Status (20)

Country Link
US (1) US7999100B2 (fr)
EP (1) EP1789395B8 (fr)
JP (1) JP2008506676A (fr)
CN (1) CN100582095C (fr)
AR (1) AR050170A1 (fr)
AT (1) ATE420864T1 (fr)
AU (1) AU2005261497A1 (fr)
BR (1) BRPI0513383A (fr)
CA (1) CA2574002C (fr)
DE (1) DE602005012405D1 (fr)
DK (1) DK1789395T3 (fr)
ES (1) ES2320155T3 (fr)
GB (1) GB2416167A (fr)
HR (1) HRP20090212T1 (fr)
MX (1) MX2007000575A (fr)
PL (1) PL1789395T3 (fr)
PT (1) PT103308B (fr)
RU (1) RU2382772C2 (fr)
SI (1) SI1789395T1 (fr)
WO (1) WO2006005951A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20120022047A1 (en) * 2009-04-02 2012-01-26 Glenmark Generics Ltd Process for the purification of eslicarbazepine acetate
EP2459198A1 (fr) 2009-07-27 2012-06-06 Bial-Portela & CA, S.A. Utilisation de dérivés de 5h-dibenz / b, f/ azépine-5-carboxamide pour le traitement de la fibromyalgie
WO2011045648A2 (fr) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Procédé de préparation de (s)-(-)-10-acétoxy-10,11-dihydro-5h-dibenz[b,f]azépine-5-carboxamide et ses esters
WO2011091131A2 (fr) * 2010-01-23 2011-07-28 Dr. Reddy's Laboratories Ltd. Acétate d'eslicarbazépine et ses polymorphes
WO2011117885A1 (fr) * 2010-03-23 2011-09-29 Intas Pharmaceuticals Limited Procédé de préparation d'énantiomères de licarbazépine
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
WO2012156987A2 (fr) * 2011-05-19 2012-11-22 Glenmark Generics Limited Nouveau procédé de préparation d'eslicarbazépine
WO2013008194A2 (fr) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Procédé de préparation et de purification d'acétate d'eslicarbazépine et de ses intermédiaires
EP2900640A1 (fr) 2012-09-26 2015-08-05 Ranbaxy Laboratories Limited Procédé de préparation d'oxcarbazépine et son utilisation en tant qu'intermédiaire dans la préparation d'acétate d'eslicarbazépine
EP3064490A1 (fr) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé amélioré pour la préparation d'eslicarbazépine et d'acétate d'eslicarbazépine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
GB0111566D0 (en) * 2001-05-11 2001-07-04 Portela & Ca Sa Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide

Also Published As

Publication number Publication date
ATE420864T1 (de) 2009-01-15
PL1789395T3 (pl) 2009-06-30
AR050170A1 (es) 2006-10-04
AU2005261497A1 (en) 2006-01-19
BRPI0513383A (pt) 2008-05-06
CA2574002C (fr) 2014-02-04
JP2008506676A (ja) 2008-03-06
PT103308B (pt) 2008-06-11
RU2007105228A (ru) 2008-08-20
CN100582095C (zh) 2010-01-20
DK1789395T3 (da) 2009-04-20
DE602005012405D1 (de) 2009-03-05
US20080293934A1 (en) 2008-11-27
US7999100B2 (en) 2011-08-16
EP1789395B8 (fr) 2009-08-12
GB0415664D0 (en) 2004-08-18
HRP20090212T1 (hr) 2009-09-30
CN101023061A (zh) 2007-08-22
EP1789395A1 (fr) 2007-05-30
SI1789395T1 (sl) 2009-06-30
MX2007000575A (es) 2007-03-30
RU2382772C2 (ru) 2010-02-27
WO2006005951A1 (fr) 2006-01-19
EP1789395B1 (fr) 2009-01-14
ES2320155T3 (es) 2009-05-19
PT103308A (pt) 2007-01-31
GB2416167A (en) 2006-01-18

Similar Documents

Publication Publication Date Title
CA2574002C (fr) Procede d&#39;inversion chirale de (s)-(+)- et (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide et melanges optiquement enrichis de ceux-ci
US7820813B2 (en) Method for preparation of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide
US8367821B2 (en) Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation
AU2002253397A1 (en) Method for preparation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide
US7189846B2 (en) Method for racemization of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5h-dibenz[B,F]azepine-5-carboxamide and optically enriched mixtures thereof
KR20070032370A (ko) (Ｓ)-(＋)- 및(Ｒ)-(-)-10,11-디히드로-10-히드록시-5Ｈ-디벤즈/ｂ,ｆ/아제핀-5-카르복스아미드 및 이들의 광학적으로 풍부한혼합물의 키랄 전환 방법

Legal Events

Date Code Title Description
EEER Examination request